Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck & Co.'s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use has been approved by Japan's Ministry of Health, Labor and Welfare for all indications previously approved for KEYTRUDA. KEYJECT, the planned trademark for KEYTRUDA QLEX in Japan, can be administered in as little
Japan's health ministry has approved Merck & Co.'s subcutaneous Keytruda QLEX (KEYTRUDA) for all approved Keytruda indications in Japan. The product, to be marketed as Keyject, can be administered in 1 minute every 3 weeks or 2 minutes every 6 weeks.
Japan’s MHLW approved Merck’s KEYTRUDA QLEX (subcutaneous pembrolizumab combo) for all existing Keytruda indications in Japan, enabling 1–2 minute injections.
Merck said Japan’s MHLW approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous administration for all KEYTRUDA indications approved in Japan.